C
Chiaki Maeyashiki
Researcher at Tokyo Medical and Dental University
Publications - 48
Citations - 569
Chiaki Maeyashiki is an academic researcher from Tokyo Medical and Dental University. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 9, co-authored 31 publications receiving 289 citations.
Papers
More filters
Journal ArticleDOI
TNFAIP3 promotes survival of CD4 T cells by restricting MTOR and promoting autophagy
Yu Matsuzawa,Shigeru Oshima,Masahiro Takahara,Chiaki Maeyashiki,Yasuhiro Nemoto,Masanori Kobayashi,Yoichi Nibe,Kengo Nozaki,Takashi Nagaishi,Ryuichi Okamoto,Kiichiro Tsuchiya,Tetsuya Nakamura,Averil Ma,Mamoru Watanabe +13 more
TL;DR: Results indicate that TNFAIP3 promotes autophagy after T cell receptor (TCR) stimulation in CD4 T cells, and illustrate that TN FAIP3 restricts MTOR signaling and promotes autophileagy, providing new insight into the manner in which MTOR and autophagic regulate survival in CD 4 T cells.
Journal ArticleDOI
The ubiquitin hybrid gene UBA52 regulates ubiquitination of ribosome and sustains embryonic development.
Masanori Kobayashi,Shigeru Oshima,Chiaki Maeyashiki,Yoichi Nibe,Kana Otsubo,Yu Matsuzawa,Yasuhiro Nemoto,Takashi Nagaishi,Ryuichi Okamoto,Kiichiro Tsuchiya,Tetsuya Nakamura,Mamoru Watanabe +11 more
TL;DR: It is demonstrated that the Ubiquitin-coding gene UBA52 is not just an ubiquitin supplier to the ubiquit in pool but is also a regulator of the ribosomal protein complex.
Journal ArticleDOI
Relative dose intensity over the first four weeks of lenvatinib therapy is a factor of favorable response and overall survival in patients with unresectable hepatocellular carcinoma
Sakura Kirino,Kaoru Tsuchiya,Masayuki Kurosaki,Shun Kaneko,Kento Inada,Koji Yamashita,Leona Osawa,Yuka Hayakawa,Shuhei Sekiguchi,Mao Okada,Wan Wang,Mayu Higuchi,Kenta Takaura,Chiaki Maeyashiki,Nobuharu Tamaki,Yutaka Yasui,Hiroyuki Nakanishi,Jun Itakura,Yuka Takahashi,Yasuhiro Asahina,Namiki Izumi +20 more
TL;DR: 4W-RDI of lenvatinib therapy is associated with favorable radiological response and longer OS, and its association with overall survival (OS) and best response by modified Response Evaluation Criteria in Solid Tumor (mRECIST) is evaluated.
Journal ArticleDOI
RIPK3 regulates p62–LC3 complex formation via the caspase-8-dependent cleavage of p62
Yu Matsuzawa,Shigeru Oshima,Yoichi Nibe,Masanori Kobayashi,Chiaki Maeyashiki,Yasuhiro Nemoto,Takashi Nagaishi,Ryuichi Okamoto,Kiichiro Tsuchiya,Tetsuya Nakamura,Mamoru Watanabe +10 more
TL;DR: It is suggested thatRIPK3 serves as a negative regulator of selective autophagy and provides new insights into the mechanism by which RIPK3 regulates autophagic signaling.
Journal ArticleDOI
Early experience of atezolizumab plus bevacizumab therapy in Japanese patients with unresectable hepatocellular carcinoma in real-world practice
Yuka Hayakawa,Kaoru Tsuchiya,Masayuki Kurosaki,Yutaka Yasui,Shun Kaneko,Yuki Tanaka,Shun Ishido,Kento Inada,Sakura Kirino,Koji Yamashita,Tsubasa Nobusawa,Hiroaki Matsumoto,Tatsuya Kakegawa,Mayu Higuchi,Kenta Takaura,Shohei Tanaka,Chiaki Maeyashiki,Nobuharu Tamaki,Hiroyuki Nakanishi,Jun Itakura,Yuka Takahashi,Yasuhiro Asahina,Ryuichi Okamoto,Namiki Izumi +23 more
TL;DR: Patients who received atezolizumab plus bevacizumabs as 1st-line therapy had better clinical outcome than those who received in later lines, and the AFP response at 6 weeks could be a predictor of disease progression.